Nyxoah S.A. (NYXH)
NASDAQ: NYXH · IEX Real-Time Price · USD
10.10
-0.70 (-6.48%)
May 17, 2024, 4:00 PM EDT - Market closed
Nyxoah Revenue
Nyxoah had revenue of $5.57M in the twelve months ending March 31, 2024, with 78.93% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.33M with 176.87% year-over-year growth. In the year 2023, Nyxoah had annual revenue of $4.83M with 47.25% growth.
Revenue (ttm)
$5.57M
Revenue Growth
+78.93%
P/S Ratio
51.73
Revenue / Employee
$38,177
Employees
146
Market Cap
288.34M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.83M | 1.55M | 47.25% |
| Dec 31, 2022 | 3.28M | 2.31M | 238.87% |
| Dec 31, 2021 | 968.18K | 884.04K | 1,050.60% |
| Dec 31, 2020 | 84.15K | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 1.19B |
| Procaps Group | 414.10M |
| Xeris Biopharma Holdings | 171.36M |
| Sanara MedTech | 68.00M |
| SOPHiA GENETICS | 64.18M |
| Aquestive Therapeutics | 51.50M |
| MacroGenics | 43.36M |
NYXH News
- 4 days ago - Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 - GlobeNewsWire
- 8 days ago - Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024 - GlobeNewsWire
- 5 weeks ago - Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation - GlobeNewsWire
- 2 months ago - Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints - GlobeNewsWire
- 2 months ago - Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results - GlobeNewsWire
- 2 months ago - Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference - GlobeNewsWire
- 3 months ago - Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 - GlobeNewsWire